Effect of acetyl salicylic acid resistance on saphenous vein graft occlusion in patients with metabolic syndrome who had coronary bypass surgery

Basit Öğe Kaydı
dc.contributor.authorBaysal, Erkan
dc.contributor.authorYener, Ali Umit
dc.contributor.authorOzkan, Turgut
dc.contributor.authorKaran, Adnan
dc.contributor.authorAstan, Ramazan
dc.contributor.authorKeskin, Gokhan
dc.contributor.authorYener, Ozlem
dc.date.accessioned2025-01-27T19:06:00Z
dc.date.available2025-01-27T19:06:00Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPURPOSE: The goal of this study was to investigate the effect of acetyl salicylic acid (ASA) resistance on saphenous vein graft occlusion in saphenous vein graft used patients with metabolic syndrome who had CABG. ASA resistance may be higher in patients with metabolic syndrome and saphenous vein graft occlusion and this may result in adverse coronary events. MATERIAL-METHOD: 41 patients with metabolic syndrome who had previously CABG operation for whom saphenous vein graft was used and who currently used 100-300 mg/day ASA, who had postoperative angina pectoris, whose ischemia was determined by noninvasive tests and to whom coronary angiography were performed, were included in our study. The patients were divided into two groups as patients with saphenous vein graft occlusion (n:18) and the patients without saphenous vein graft occlusion (n:23). FINDINGS: In both groups with similar demographic characteristics while ASA resistance was determined in 10 patients with saphenous vein graft occlusion, 7 patients without saphenous vein graft occlusion had ASA resistance. This statistics showed us that in the patients with metabolic syndrome and who had ASA resistance, saphenous vein graft occlusion developed more. CONCLUSION: Although it is important to check ASA resistance in patients with metabolic syndrome, to whom CABG are intended, it is not checked routinely. In patients with metabolic syndrome who have ASA resistance, if CABG is planned high dose ASA treatment can be applied in early period, additional antithrombocyte treatment may be added or arterial graft may be used.
dc.identifier.endpage2654
dc.identifier.issn1205-6626
dc.identifier.issue1
dc.identifier.scopus2-s2.0-84899759910
dc.identifier.scopusqualityN/A
dc.identifier.startpage2642
dc.identifier.urihttps://hdl.handle.net/20.500.12428/14099
dc.identifier.volume20
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherPulsus Group Inc.
dc.relation.ispartofExperimental and Clinical Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250125
dc.subjectASA resistance; Coronary artery disease; Metabolic syndrome; Saphenous vein graft occlusion
dc.titleEffect of acetyl salicylic acid resistance on saphenous vein graft occlusion in patients with metabolic syndrome who had coronary bypass surgery
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu